Moreover, the high prevalence of this alteration suggests that PP2A hyperphosphorylation and CIP2A overexpression represent key mechanisms to inhibit PP2A in breast cancer, and our proposed CPscore would serve to define a subgroup of patients who might benefit from the inclusion of PP2A activators such as FTY720 in anticancer protocols for treating breast cancer patients alone or combined with an anthracycline-based chemotherapy backbones. The gene discussed is PTPA; the disease is breast carcinoma.